imatinib mesylate has been researched along with Angiomyolipoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chada, K; D'Armiento, JM; Shiomi, T; Sonett, J; Unachukwu, U; Woode, D | 1 |
| Aida, T; Miyazawa, K; Miyoshi, T; Ogasawara, T; Sato, S; Shiobara, M; Suda, K; Wakatsuki, K; Yamazaki, K; Yoshioka, S | 1 |
| Fernandez, CV; Rigby, H; Schmidt, MH; Yu, W | 1 |
3 other study(ies) available for imatinib mesylate and Angiomyolipoma
| Article | Year |
|---|---|
Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis.
Topics: Angiomyolipoma; Animals; Apoptosis; Imatinib Mesylate; Kidney Neoplasms; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; TOR Serine-Threonine Kinases; Tuberous Sclerosis; Tumor Suppressor Proteins; Tyrosine Kinase Inhibitors | 2023 |
[A Case of Gastrointestinal Stromal Tumor Re-Resected Ten Years after the Resection of Its Recurrence].
Topics: Aged; Angiomyolipoma; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2019 |
Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate.
Topics: Angiomyolipoma; Antineoplastic Agents; Benzamides; Child; Dacarbazine; Epithelioid Cells; Fatal Outcome; Female; Humans; Imatinib Mesylate; Kidney Neoplasms; Neoplasm Metastasis; Piperazines; Pyrimidines; Treatment Failure | 2005 |